Hikal Limited has reported its unaudited financial results for the quarter and half-year ended September 30, 2026. For the second quarter, the company posted a loss of ₹62 million, compared to a loss of ₹73 million in the same quarter of the previous year. The half-year results show a loss of ₹137 million. The company also provided its standalone balance sheet and cash flow statements for the relevant periods.
Hikal Limited: Q2 and H1 FY27 Financial Highlights
Hikal Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company recorded a loss for the period of ₹62 million for the quarter ended September 30, 2026. This compares to a loss of ₹73 million reported for the same quarter in the previous fiscal year. The standalone revenue from operations for the quarter stood at ₹4,359 million.
Half-Year Performance
For the half-year ended September 30, 2026, Hikal Limited reported a total comprehensive loss of ₹129 million. The revenue from operations for the half-year amounted to ₹8,405 million. The company’s standalone cash flow statement indicates net cash generated from operating activities of ₹1,668 million for the half-year ended September 30, 2026.
Consolidated Financials
On a consolidated basis, the loss for the quarter ended September 30, 2026, was ₹61 million, with total comprehensive loss for the half-year at ₹127 million. Consolidated revenue from operations for the quarter was ₹4,359 million, and for the half-year, it was ₹8,405 million. The consolidated cash flow statement shows net cash generated from operating activities of ₹1,669 million for the half-year ended September 30, 2026.
Key Notes and Auditor’s Review
The financial results were reviewed by the Audit Committee on November 2, 2026, and approved by the Board of Directors on November 3, 2026. The statutory auditors, SRBC & CO LLP, have provided a limited review report with an unmodified conclusion for both standalone and consolidated results. A note highlights an ongoing legal matter pending before the Supreme Court of India concerning environmental laws, for which no provision is deemed necessary at this stage. Additionally, a warning letter from the USFDA regarding the Jigani facility is noted to have impacted sales for the Pharma Segment.
Source: BSE
